Codiak BioSciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference

Rhea-AI Summary

On November 23, 2020, Codiak BioSciences, a clinical-stage company developing exosome-based therapeutics, announced that Douglas E. Williams, Ph.D., its President and CEO, will speak at the Evercore ISI 3rd Annual HealthCONx Conference. The fireside chat is scheduled for December 2 at 4:45 p.m. ET. A live webcast will be available on Codiak's website, with an archived replay accessible for 90 days. Codiak aims to revolutionize treatment for various diseases through its innovative engEx Platform, creating novel exosome therapeutic candidates.

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat at the Evercore ISI 3^rd Annual HealthCONx Conference. Details are as follows:

Evercore ISI 3^rd Annual HealthCONx Conference
Date: Wednesday, December 2
Time: 4:45 p.m. ET

A live webcast of the fireside chat will be available on the Investors & Media section of the Codiak website at www.codiakbio.com. An archived replay will be available for approximately 90 days following the fireside chat.   

About Codiak BioSciences
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Media Contact
Lindy Devereux
Scient PR
T: 646-515-5730
E: media@codiakbio.com

Investor Contact
Christine Labaree
Evergreen Communications
T: 650-600-1697
E: investor@codiakbio.com

FAQ

What is the date and time of Codiak BioSciences' participation in the Evercore ISI HealthCONx Conference?

Codiak BioSciences will participate in the Evercore ISI HealthCONx Conference on December 2, 2020, at 4:45 p.m. ET.

Where can I watch the Codiak BioSciences fireside chat?

The fireside chat can be viewed live on Codiak BioSciences' website under the Investors & Media section.

How long will the Codiak BioSciences fireside chat replay be available?

The archived replay of the fireside chat will be available for approximately 90 days after the event.

Who is representing Codiak BioSciences at the HealthCONx Conference?

Douglas E. Williams, Ph.D., the President and CEO of Codiak BioSciences, will represent the company at the conference.

What therapeutic approaches is Codiak BioSciences focused on?

Codiak BioSciences is focused on developing exosome-based therapeutics to address a variety of diseases with high unmet medical needs.